Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 11/2020

Open Access 01-11-2020 | Magnetic Resonance Imaging | Special Section : Diffuse Liver Disease

Quantification of liver function using gadoxetic acid-enhanced MRI

Authors: Sarah Poetter-Lang, Nina Bastati, Alina Messner, Antonia Kristic, Alexander Herold, Jacqueline C. Hodge, Ahmed Ba-Ssalamah

Published in: Abdominal Radiology | Issue 11/2020

Login to get access

Abstract

The introduction of hepatobiliary contrast agents, most notably gadoxetic acid (GA), has expanded the role of MRI, allowing not only a morphologic but also a functional evaluation of the hepatobiliary system. The mechanism of uptake and excretion of gadoxetic acid via transporters, such as organic anion transporting polypeptides (OATP1,3), multidrug resistance-associated protein 2 (MRP2) and MRP3, has been elucidated in the literature. Furthermore, GA uptake can be estimated on either static images or on dynamic imaging, for example, the hepatic extraction fraction (HEF) and liver perfusion. GA-enhanced MRI has achieved an important role in evaluating morphology and function in chronic liver diseases (CLD), allowing to distinguish between the two subgroups of nonalcoholic fatty liver diseases (NAFLD), simple steatosis and nonalcoholic steatohepatitis (NASH), and help to stage fibrosis and cirrhosis, predict liver transplant graft survival, and preoperatively evaluate the risk of liver failure if major resection is planned. Finally, because of its noninvasive nature, GA-enhanced MRI can be used for long-term follow-up and post-treatment monitoring. This review article aims to describe the current role of GA-enhanced MRI in quantifying liver function in a variety of hepatobiliary disorders.
Literature
1.
Van Beers BE, Daire JL, Garteiser P: New imaging techniques for liver diseases. J Hepatol 2015, 62(3):690-700.PubMedCrossRef
2.
Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W: Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. European radiology 2009, 19(2):342-357.PubMedCrossRef
3.
Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB: MR contrast agents for liver imaging: what, when, how. Radiographics 2006, 26(6):1621-1636.PubMedCrossRef
4.
Semelka RC, Helmberger TK: Contrast agents for MR imaging of the liver. Radiology 2001, 218(1):27-38.PubMedCrossRef
5.
Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV: Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics : a review publication of the Radiological Society of North America, Inc 2009, 29(6):1725–1748.
6.
Ba-Ssalamah A, Qayyum A, Bastati N, Fakhrai N, Herold CJ, Caseiro Alves F: P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker. Expert Rev Gastroenterol Hepatol 2014, 8(2):147-160.PubMedCrossRef
7.
Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB et al: Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma. European radiology 2014, 24(9):2146-2156.PubMedCrossRef
8.
Zhang T, Runge JH, Lavini C, Stoker J, van Gulik T, Cieslak KP, van Vliet LJ, Vos FM: A pharmacokinetic model including arrival time for two inputs and compensating for varying applied flip-angle in dynamic gadoxetic acid-enhanced MR imaging. PLoS One 2019, 14(8):e0220835.PubMedPubMedCentralCrossRef
9.
Zech CJ, Vos B, Nordell A, Urich M, Blomqvist L, Breuer J, Reiser MF, Weinmann HJ: Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009, 44(6):305-310.PubMedCrossRef
10.
Lee NK, Kim S, Lee JW, Lee SH, Kang DH, Kim GH, Seo HI: Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics : a review publication of the Radiological Society of North America, Inc 2009, 29(6):1707–1724.
11.
Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K: Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. European radiology 2010, 20(11):2690-2698.PubMedCrossRef
12.
Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE: Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 2011, 46(9):548-555.PubMedCrossRef
13.
Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, Kitamura T, Amemiya F, Enomoto N, Matsuda M et al: Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011, 46(2):141-145.PubMedCrossRef
14.
Sourbron S, Sommer WH, Reiser MF, Zech CJ: Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 2012, 263(3):874-883.PubMedCrossRef
15.
Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, Cipriano MA, Wrba F, Trauner M, Herold CJ et al: Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging. Radiology 2015, 277(1):104-113.PubMedCrossRef
16.
Van Beers BE, Pastor CM, Hussain HK: Primovist, Eovist: what to expect?Journal of hepatology 2012, 57(2):421-429.PubMedCrossRef
17.
Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K et al: Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010, 255(3):824-833.PubMedCrossRef
18.
Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, Elmer MC, Semmler G, Simbrunner B, Hodge JC et al: Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019, 29(12):6600-6610.PubMedPubMedCentralCrossRef
19.
Verloh N, Probst U, Utpatel K, Zeman F, Brennfleck F, Werner JM, Fellner C, Stroszczynski C, Evert M, Wiggermann P et al: Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 2019, 14(5):e0215752.PubMedPubMedCentralCrossRef
20.
Feier D, Balassy C, Bastati N, Stift J, Badea R, Ba-Ssalamah A: Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology 2013, 269(2):460-468.PubMedCrossRef
21.
Kukuk GM, Schaefer SG, Fimmers R, Hadizadeh DR, Ezziddin S, Spengler U, Schild HH, Willinek WA: Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. European radiology 2014, 24(10):2482-2490.PubMedCrossRef
22.
Verloh N, Haimerl M, Zeman F, Schlabeck M, Barreiros A, Loss M, Schreyer AG, Stroszczynski C, Fellner C, Wiggermann P: Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. European radiology 2014, 24(5):1013-1019.PubMedCrossRef
23.
Yoon JH, Lee JM, Kang HJ, Ahn SJ, Yang H, Kim E, Okuaki T, Han JK: Quantitative Assessment of Liver Function by Using Gadoxetic Acid-enhanced MRI: Hepatocyte Uptake Ratio. Radiology 2019, 290(1):125-133.PubMedCrossRef
24.
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE: Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?J Magn Reson Imaging 2017, 45(3):646-659.PubMedCrossRef
25.
Zhou ZP, Long LL, Qiu WJ, Cheng G, Huang LJ, Yang TF, Huang ZK: Comparison of 10- and 20-min hepatobiliary phase images on Gd-EOB-DTPA-enhanced MRI T1 mapping for liver function assessment in clinic. Abdom Radiol (NY) 2017, 42(9):2272-2278.CrossRef
26.
Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T et al: Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. European radiology 2020, 30(1):370-382.PubMedCrossRef
27.
Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, Rockenschaub S, Berlakovich GA, Trauner M, Herold C et al: Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. Invest Radiol 2016, 51(11):728-734.PubMedCrossRef
28.
Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y, Elmer MC, Einspieler H, Semmler G, Simbrunner B et al: Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?Radiology 2020, 294(1):98-107.PubMedCrossRef
29.
Wibmer A, Nolz R, Trauner M, Ba-Ssalamah A: [Functional MR imaging of the liver]. Der Radiologe 2015, 55(12):1057-1066.PubMedCrossRef
30.
Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A: Liver Failure after Major Liver Resection: Risk Assessment by Using Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging. Radiology 2013, 269(3):777-786.PubMedCrossRef
31.
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM et al: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124(1):91-96.PubMedCrossRef
32.
Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T: Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 2011, 46(4):277-283.PubMedCrossRef
33.
Kim JE, Kim HO, Bae K, Choi DS, Nickel D: T1 mapping for liver function evaluation in gadoxetic acid-enhanced MR imaging: comparison of look-locker inversion recovery and B1 inhomogeneity-corrected variable flip angle method. European radiology 2019, 29(7):3584-3594.PubMedCrossRef
34.
Haimerl M, Fuhrmann I, Poelsterl S, Fellner C, Nickel MD, Weigand K, Dahlke MH, Verloh N, Stroszczynski C, Wiggermann P: Gd-EOB-DTPA-enhanced T1 relaxometry for assessment of liver function determined by real-time (13)C-methacetin breath test. European radiology 2018, 28(9):3591-3600.PubMedCrossRef
35.
Peng Y, Qi X, Guo X: Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore) 2016, 95(8):e2877.CrossRef
36.
Kim DK, Choi JI, Choi MH, Park MY, Lee YJ, Rha SE, Jung SE: Prediction of Posthepatectomy Liver Failure: MRI With Hepatocyte-Specific Contrast Agent Versus Indocyanine Green Clearance Test. AJR Am J Roentgenol 2018, 211(3):580-587.PubMedCrossRef
37.
Theilig D, Elkilany A, Schmelzle M, Muller T, Hamm B, Denecke T, Geisel D: Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. Abdom Radiol (NY) 2019, 44(8):2759-2768.CrossRef
38.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381(9865):468-475.PubMedCrossRef
39.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64(1):73-84.PubMedCrossRef
40.
Ahmed A, Wong RJ, Harrison SA: Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015, 13(12):2062-2070.CrossRef
41.
Lewis JR, Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010, 55(3):560-578.PubMedCrossRef
42.
Bastati N, Feier D, Wibmer A, Traussnigg S, Balassy C, Tamandl D, Einspieler H, Wrba F, Trauner M, Herold C et al: Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2014, 271(3):739-747.PubMedCrossRef
43.
Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N et al: Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020.
44.
Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS: Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. European radiology 2014, 24(4):959-966.PubMedCrossRef
45.
Wu Z, Matsui O, Kitao A, Kozaka K, Koda W, Kobayashi S, Ryu Y, Minami T, Sanada J, Gabata T: Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis. J Magn Reson Imaging 2013, 37(5):1137-1143.PubMedCrossRef
46.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F: The burden of liver disease in Europe: a review of available epidemiological data. Journal of hepatology 2013, 58(3):593-608.PubMedCrossRef
47.
Kovac JD, Dakovic M, Stanisavljevic D, Alempijevic T, Jesic R, Seferovic P, Maksimovic R: Diffusion-weighted MRI versus transient elastography in quantification of liver fibrosis in patients with chronic cholestatic liver diseases. European journal of radiology 2012, 81(10):2500-2506.PubMedCrossRef
48.
Van Beers BE, Garteiser P, Leporq B, Rautou PE, Valla D: Quantitative Imaging in Diffuse Liver Diseases. Semin Liver Dis 2017, 37(3):243-258.PubMedCrossRef
49.
Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW: Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014, 39(3):254-269.PubMedCrossRef
50.
Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH et al: Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018, 68(1):349-360.PubMedPubMedCentralCrossRef
51.
Vilar-Gomez E, Chalasani N: Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of hepatology 2018, 68(2):305-315.PubMedCrossRef
52.
Li S, Sun X, Chen M, Ying Z, Wan Y, Pi L, Ren B, Cao Q: Liver Fibrosis Conventional and Molecular Imaging Diagnosis Update. J Liver 2019, 8(1).
53.
Yang D, Li D, Li J, Yang Z, Wang Z: Systematic review: The diagnostic efficacy of gadoxetic acid-enhanced MRI for liver fibrosis staging. European journal of radiology 2020, 125:108857.PubMedCrossRef
54.
Feier D, Balassy C, Bastati N, Fragner R, Wrba F, Ba-Ssalamah A: The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach. European radiology 2016, 26(2):539-546.PubMedCrossRef
55.
Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT: Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology 2011, 259(1):142-150.PubMedCrossRef
56.
Hoffman DH, Ayoola A, Nickel D, Han F, Chandarana H, Shanbhogue KP: T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis. Abdom Radiol (NY) 2020, 45(3):692-700.CrossRef
57.
Ding Y, Rao SX, Zhu T, Chen CZ, Li RC, Zeng MS: Liver fibrosis staging using T1 mapping on gadoxetic acid-enhanced MRI compared with DW imaging. Clinical radiology 2015, 70(10):1096-1103.PubMedCrossRef
58.
Mohamadnejad M, Tavangar SM, Sotoudeh M, Kosari F, Khosravi M, Geramizadeh B, Montazeri G, Estakhri A, Mirnasseri MM, Fazlollahi A et al: Histopathological Study of Chronic Hepatitis B: A Comparative Study of Ishak and METAVIR Scoring Systems. Int J Organ Transplant Med 2010, 1(4):171-176.PubMedPubMedCentral
59.
Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN: The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012, 57(3):556-563.PubMedCrossRef
60.
Theise ND, Jia J, Sun Y, Wee A, You H: Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol 2018, 31(8):1191-1200.PubMedCrossRef
61.
Garcia-Tsao G, Friedman S, Iredale J, Pinzani M: Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51(4):1445-1449.PubMedPubMedCentralCrossRef
62.
Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA: Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013, 11(12):1573–1584 e1571–1572; quiz e1588–1579.
63.
Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stattermayer AF, Reiberger T, Beinhardt S et al: Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of hepatology 2016, 65(4):692-699.PubMedCrossRef
64.
Mandorfer M, Kozbial K, Freissmuth C, Schwabl P, Stattermayer AF, Reiberger T, Beinhardt S, Schwarzer R, Trauner M, Ferlitsch A et al: Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther 2015, 42(6):707-718.PubMedCrossRef
65.
Haider L, Mandorfer M, Gungoren Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M et al: Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. Contrast Media Mol Imaging 2018, 2018:8489709.PubMedPubMedCentralCrossRef
66.
Truhn D, Kuhl CK, Ciritsis A, Barabasch A, Kraemer NA: A New Model for MR Evaluation of Liver Function with Gadoxetic Acid, Including Both Uptake and Excretion. European radiology 2019, 29(1):383-391.PubMedCrossRef
67.
Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, Higashi H, Sone T: Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. European journal of radiology 2011, 80(3):e311-316.PubMedCrossRef
68.
Tsuda N, Okada M, Murakami T: New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. European journal of radiology 2010, 73(1):137-142.PubMedCrossRef
69.
Kanki A, Tamada T, Higaki A, Noda Y, Tanimoto D, Sato T, Higashi H, Ito K: Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012, 30(3):356-360.PubMedCrossRef
70.
Besa C, Bane O, Jajamovich G, Marchione J, Taouli B: 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function. Magn Reson Imaging 2015, 33(9):1075-1082.PubMedCrossRef
71.
Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, Hocquelet A, Juanola E, Foucher J, Laurent F et al: MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity. European journal of radiology 2015, 84(8):1459-1465.PubMedCrossRef
72.
Heye T, Yang SR, Bock M, Brost S, Weigand K, Longerich T, Kauczor HU, Hosch W: MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. European radiology 2012, 22(6):1224-1232.PubMedCrossRef
73.
Sandrasegaran K, Cui E, Elkady R, Gasparis P, Borthakur G, Tann M, Liangpunsakul S: Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?European radiology 2018, 28(10):4215-4224.PubMedCrossRef
74.
Asenbaum U, Kaczirek K, Ba-Ssalamah A, Ringl H, Schwarz C, Waneck F, Fitschek F, Loewe C, Nolz R: Post-hepatectomy liver failure after major hepatic surgery: not only size matters. European radiology 2018, 28(11):4748-4756.PubMedPubMedCentralCrossRef
75.
Costa AF, Tremblay St-Germain A, Abdolell M, Smoot RL, Cleary S, Jhaveri KS: Can contrast-enhanced MRI with gadoxetic acid predict liver failure and other complications after major hepatic resection?Clinical radiology 2017, 72(7):598-605.PubMedCrossRef
76.
Theilig D, Steffen I, Malinowski M, Stockmann M, Seehofer D, Pratschke J, Hamm B, Denecke T, Geisel D: Predicting liver failure after extended right hepatectomy following right portal vein embolization with gadoxetic acid-enhanced MRI. European radiology 2019, 29(11):5861-5872.PubMedCrossRef
77.
O'Rourke TR, Welsh FK, Tekkis PP, Lyle N, Mustajab A, John TG, Peppercorn D, Rees M: Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol 2009, 35(10):1085-1091.PubMedCrossRef
78.
Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, Huang SY, Mahvash A, Gupta S, Wallace MJ et al: Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013, 20(8):2493-2500.PubMedCrossRef
79.
Cho SH, Kang UR, Kim JD, Han YS, Choi DL: The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study. European journal of radiology 2011, 80(2):e195-200.PubMedCrossRef
80.
Boraschi P, Della Pina MC, Donati F: Graft complications following orthotopic liver transplantation: Role of non-invasive cross-sectional imaging techniques. European journal of radiology 2016, 85(7):1271-1283.PubMedCrossRef
81.
Nolz R, Asenbaum U, Schoder M, Wibmer A, Einspieler H, Prusa AM, Peck-Radosavljevic M, Ba-Ssalamah A: Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. Clinical radiology 2014, 69(5):499-508.PubMedCrossRef
82.
Pandey P, Pandey A, Dillhoff M, Schmidt C, Kamel IR, Pawlik TM: Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy. J Gastrointest Surg 2018, 22(2):344-360.PubMedCrossRef
83.
Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK: Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 2013, 266(2):452-461.PubMedCrossRef
84.
Ringe KI, von Falck C, Raatschen HJ, Wacker F, Hinrichs J: Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI-Influence of different contrast agent application protocols. PLoS One 2018, 13(7):e0200887.PubMedPubMedCentralCrossRef
85.
Polanec SH, Bickel H, Baltzer PAT, Thurner P, Gittler F, Hodge JC, Bashir MR, Ba-Ssalamah A: Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: Can the injection protocol minimize this drawback?J Magn Reson Imaging 2017, 46(4):1107-1114.PubMedCrossRef
Metadata
Title
Quantification of liver function using gadoxetic acid-enhanced MRI
Authors
Sarah Poetter-Lang
Nina Bastati
Alina Messner
Antonia Kristic
Alexander Herold
Jacqueline C. Hodge
Ahmed Ba-Ssalamah
Publication date
01-11-2020
Publisher
Springer US
Published in
Abdominal Radiology / Issue 11/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02779-x

Other articles of this Issue 11/2020

Abdominal Radiology 11/2020 Go to the issue

Special Section: Chronic liver disease

Natural history of hepatocellular carcinoma after stereotactic body radiation therapy

Hepatobiliary

Combination of hepatocyte fraction and diffusion-weighted imaging as a predictor in quantitative hepatic fibrosis evaluation

Review

Multiparametric magnetic resonance imaging of endometrial polypoid lesions

Letter to the Editor

Liver regeneration in recipients after living-donor liver transplantation in using preoperative CT texture analysis and clinical features; methodological issues on prediction

Hepatobiliary

Prediction of liver regeneration in recipients after living-donor liver transplantation in using preoperative CT texture analysis and clinical features

Spleen

Relationship between magnetic resonance imaging spleen T1 relaxation and other radiologic and clinical biomarkers of liver fibrosis in children and young adults with autoimmune liver disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits